NCT03679312View on ClinicalTrials.gov

The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 4, 2018

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2023

Conditions
Dyspnea
Interventions
DRUG

Nitric Oxide

Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.

DRUG

Placebo

Inhaled placebo, which consists of breathing medical grade air (21% O2).

Trial Locations (1)

t5r2j3

Clinical Sciences Building, Edmonton

All Listed Sponsors
collaborator

University Hospital Foundation

OTHER

collaborator

Canadian Lung Association

INDUSTRY

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University of Alberta

OTHER

NCT03679312 - The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD | Biotech Hunter | Biotech Hunter